antagonists – Page 4 – Communicable Diseases Research

Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study

코로나19 환자의 용도 변경 및 보조제 사용: 다국적 네트워크 코호트 연구

Research

Published on 2021-05-112022-09-10
Journal: The BMJ [Category] Fulltext, SARS, 신약개발,

PIMS-TS, the New Paediatric Systemic Inflammatory Disease Related to Previous Exposure to SARS-CoV-2 Infection—“Rheumatic Fever” of the 21st Century?

SARS-CoV-2 감염에 대한 이전 노출과 관련된 새로운 소아 전신 염증 질환인 PIMS-TS - 21세기의 "류마티스 열"?

Review

Published on 2021-04-262022-09-12
Journal: International Journal of Molecular Sciences [Category] MERS, SARS, 진단,

[키워드] abnormal immune response acute respiratory syndrome acute respiratory syndrome coronavirus acute rheumatic fever Affect antagonists Anti-inflammatory anti-inflammatory treatment ARF article blockers can be used children coronavirus Course courses COVID-19 current current therapy disease Efficacy and safety exposure to feature Fever glucocorticoid Glucocorticoids IL-6 IL-6 receptor Immunoglobulin Inflammatory inflammatory disease interleukin intravenous Intravenous immunoglobulin management Necrosis New paediatric inflammatory multisystem syndrome paediatric inflammatory multisystemic syndrome (PIMS) pathogen Pathogenesis Pathogens Patient PIMS Prophylaxis question rheumatic fever SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Symptom syndrome systemic systemic inflammatory the vaccine therapy
[DOI] 10.3390/ijms22094488 PMC 바로가기 [Article Type] Review

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

코비드-19에 걸린 중환자의 인터루킨-6 수용체 길항제

Randomized Controlled Trial

Published on 2021-04-222022-09-12
Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 임상, 진단,

[키워드] 24 hour Adaptive platform trial adjusted Adult patient Analysis antagonist antagonists assigned Bayesian control group coronavirus disease criteria Critically ill patient cumulative odds ratio Efficacy evaluated greater groups hazard ratio ICU ICUs Ill In-hospital death intensive care interleukin-6 receptor International interquartile range median multifactorial Odds ratio organ organ support outcomes Patient posterior probability Primary outcome Randomly receive receiving REMAP-CAP sarilumab secondary analysis standard care statistical model supported survival Tocilizumab Treatment Trial yielding
[DOI] 10.1056/NEJMoa2100433 PMC 바로가기 [Article Type] Randomized Controlled Trial

SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial-derived cells and cardiomyocytes

423

Published on 2021-04-202022-10-29
Journal: Proceedings of the National Academy of Sciences of [Category] COVID-19, SARS,

[키워드] A549 ACE2 activate activated Activation alveolar antagonists Antiviral Calu-3 Cell cell lines cell types cells characterized consequence contribute Coronavirus infection COVID-19 disease COVID-19 pandemic Cytopathic effect Defense double-stranded dysregulated Effect Health Host host–virus interaction IFN IFN response IFN signaling induce infect inhibit initial innate immune innate immune response Interaction interferon interferon signaling genes Invasion knowledge lung; MAVS MERS-CoV Middle East mutant Nasal Epithelial cells OAS-RNase L other coronaviruses pathogenesis of SARS-CoV-2 pathway Pathways PKR Protein Replication response RNASEL SARS-CoV-2 severe COVID-19 disease Signaling Significance syndrome unique viral double-stranded RNA virus while
[DOI] 10.1073/pnas.2022643118 PMC 바로가기 [Article Type] 423

The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19

Medicine

Published on 2021-03-312022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

Viral genomic, metagenomic and human transcriptomic characterization and prediction of the clinical forms of COVID-19

COVID-19의 임상 형태에 대한 바이러스 게놈, 메타게놈 및 인간 전사체 특성화 및 예측

Clinical Trial

Published on 2021-03-292022-09-10
Journal: PLoS Pathogens [Category] SARS, 유전자 메커니즘, 임상, 치료기술,

[키워드] activate activating acute respiratory distress syndrome Acute respiratory failure Analysis antagonists Bacteria candidate Candidates caused Characteristics characterized clinical form collected COVID-19 COVID-19 pneumonia CXCR2 cytokine Diagnosis disease distress ENhance Factor feature female gender form fungi Genetic genomic high mortality rate Host identify IL-8 Immune cell immune cells infiltration Inflammatory response intensive care intensive care unit lower mortality metagenomic Mild Nasopharyngeal swab nasopharyngeal swabs neutrophil neutrophil infiltration outpatients overactive overexpression pandemic parasite parasites pathophysiology pathway Patient patients hospitalized Pneumonia pulmonary disease receptor respiratory respiratory distress Respiratory distress syndrome Respiratory failure respiratory symptom respiratory symptoms resulting SARS-CoV-2 Severe case severe COVID-19 Severe COVID-19 pneumonia severe pneumonia severity severity of COVID-19 shotgun syndrome T helper the disease tissue damage transcript transcriptomic transcriptomics Treatment turn upper respiratory Viral viruses was performed were used
[DOI] 10.1371/journal.ppat.1009416 PMC 바로가기 [Article Type] Clinical Trial

An open label trial of anakinra to prevent respiratory failure in COVID-19

COVID-19에서 호흡 부전을 예방하기 위한 아나킨라의 공개 라벨 시험

Clinical Trial

Published on 2021-03-082022-08-13
Journal: eLife [Category] SARS, 바이오마커, 임상,

[키워드] 30-Day mortality 95% CI Administering Anakinra antagonists approach Arthritis assigned balance Biomarker blood protein blood sample Care cause circulating class clinical Combination COVID-19 COVID-19 patients death rate death rates decrease defined develop drug effective examined form framework funding hazard ratio help highest Horizon Human identify immune function immune response immune system IMPROVE incidence individual infected individual Infection Inflammation Inflammatory Inflammatory mediators injection interleukin-10 investigated less marker medication medications non-invasive ventilation once daily open label outcome Pain Patient Pneumonia Prevent Primary outcome progressed progression Protein receptor reduce reduced respiratory Respiratory failure respiratory ratio respond restored rheumatoid arthritis risk risk of death Safe SARS-CoV-2 SARS-CoV-2 virus secondary outcome Sepsis severe respiratory failure Side effects significantly SOFA SOFA score soluble urokinase plasminogen activator receptor SRF suggested suPAR Swedish Orphan Biovitrum swelling the SARS-CoV-2 virus treat treating COVID-19 patient Treatment Trial ventilator while WHO-CPS
[DOI] 10.7554/eLife.66125 PMC 바로가기 [Article Type] Clinical Trial

Inhibition of anti-viral stress granule formation by coronavirus endoribonuclease nsp15 ensures efficient virus replication

코로나바이러스 엔도리보뉴클레아제 nsp15에 의한 항바이러스 스트레스 과립 형성 억제로 효율적인 바이러스 복제 보장

Research Article

Published on 2021-02-262022-08-13
Journal: PLoS Pathogens [Category] Biochemistry, MERS, 치료법,

[키워드] accumulation Activation affected aggregation Analysis antagonist antagonists Anti-viral Antiviral array cells conserved coronavirus Coronavirus infection Coronaviruses Critical Crosstalk decrease demonstrated Depletion dsRNA eIF2α ENCODE endoribonuclease Evidence Factors function Heat shock Host host antiviral response host cell host response IBV IBV infection IFN response IFN-β immune response immunofluorescence analysis include increase infected cells Infection Infectious Bronchitis Virus inhibiting inhibition innate immune interfere Interference intrinsic IRF3 knowledge mechanism mRNAs NaCl Nsp15 overcome overexpressed Pattern recognition pattern recognition receptor Pattern recognition receptors PEDV Phosphorylation PKR prevalent Prevent Protein protein synthesis provided PRRs Recognition recruitment reducing Replication reported responsible RNA viruses SARS-CoV SARS-CoV-2 scaffold proteins shown Signaling sodium sodium arsenite Stress stress granule stress response suppression TGEV Transcription translation Trigger triggered turn Viral viral dsRNA virus virus replication viruses wild type
[DOI] 10.1371/journal.ppat.1008690 PMC 바로가기 [Article Type] Research Article

Review of Medical Therapies for the Management of Pulmonary Embolism

Review

Published on 2021-01-262022-10-30
Journal: Medicina [Category] Coronavirus,

Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19

인터루킨-18의 예후 가치와 코로나19의 다른 염증 표지자 및 질병 중증도와의 연관성

Article

Published on 2021-01-012022-09-11
Journal: Cytokine [Category] MERS, 바이오마커,

[키워드] Admission age and sex analyzed antagonist antagonists approach association Asymptomatic biochemical marker biochemical markers blood sample Blood samples Care Characteristics Clinical characteristics clinical trial clinical trials collected Concentration consequence control group correlated COVID-19 COVID-19 pathogenesis COVID-19 patient COVID-19 patients creatinine CRP cut off value cytokine Cytokines D-dimer death defined demographic and clinical characteristics determined by detrimental Diagnosis died dimer disease disease severity ELISA enrolled Enrollment Evidence feature ferritin healthy subject healthy subjects highest hospital discharge ICU ICU admission IL-18 IL-6 immune response increased risk individual Inflammatory marker inflammatory markers intensive care intensive care unit interleukin Interleukin-18 Laboratory lead liver enzyme liver enzymes Macrophage macrophage activation syndrome male median age Mild mild pneumonia nine nucleic acid on admission organ organ injury outcome Patient Pneumonia procalcitonin Prognosis radiological required Result RT-PCR SARS-CoV-2 nucleic acid serum serum concentrations Serum level serum levels severe COVID-19 patients severe group severe pneumonia study population three group three groups Treatment troponin Viral viral infections were measured with COVID-19
[DOI] 10.1016/j.cyto.2020.155302 PMC 바로가기 [Article Type] Article